409 related articles for article (PubMed ID: 25135991)
21. Stage I testicular seminoma: results of adjuvant irradiation and surveillance.
Warde P; Gospodarowicz MK; Panzarella T; Catton CN; Sturgeon JF; Moore M; Goodman P; Jewett MA
J Clin Oncol; 1995 Sep; 13(9):2255-62. PubMed ID: 7666083
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.
Chung P; Daugaard G; Tyldesley S; Atenafu EG; Panzarella T; Kollmannsberger C; Warde P
Cancer Med; 2015 Jan; 4(1):155-60. PubMed ID: 25236854
[TBL] [Abstract][Full Text] [Related]
23. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fosså SD; Germà-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondruš D; Rosti G; Stephenson AJ; Tandstad T
Ann Oncol; 2015 May; 26(5):833-838. PubMed ID: 25378299
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.
Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Carus A; Rosenvilde JJ; Berney D; Daugaard G
Eur J Cancer; 2024 May; 202():114025. PubMed ID: 38531266
[TBL] [Abstract][Full Text] [Related]
25. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
Aparicio J; Germà JR; García del Muro X; Maroto P; Arranz JA; Sáenz A; Barnadas A; Dorca J; Gumà J; Olmos D; Bastús R; Carles J; Almenar D; Sánchez M; Paz-Ares L; Satrústegui JJ; Mellado B; Balil A; López-Brea M; Sánchez A;
J Clin Oncol; 2005 Dec; 23(34):8717-23. PubMed ID: 16260698
[TBL] [Abstract][Full Text] [Related]
26. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study.
Aparicio J; Sánchez-Muñoz A; Gumà J; Domenech M; Meana JA; García-Sánchez J; Bastús R; Gironés R; González-Billalabeitia E; Sagastibelza N; Ochenduszko S; Sánchez A; Terrasa J; Germà-Lluch JR; García Del Muro X;
Oncology; 2018; 95(1):8-12. PubMed ID: 29587278
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).
Aparicio J; Maroto P; García Del Muro X; Sánchez-Muñoz A; Gumà J; Margelí M; Sáenz A; Sagastibelza N; Castellano D; Arranz JA; Hervás D; Bastús R; Fernández-Aramburo A; Sastre J; Terrasa J; López-Brea M; Dorca J; Almenar D; Carles J; Hernández A; Germà JR
Ann Oncol; 2014 Nov; 25(11):2173-2178. PubMed ID: 25210015
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
Warde P; Specht L; Horwich A; Oliver T; Panzarella T; Gospodarowicz M; von der Maase H
J Clin Oncol; 2002 Nov; 20(22):4448-52. PubMed ID: 12431967
[TBL] [Abstract][Full Text] [Related]
29. Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer.
Escudero-Ávila R; Rodríguez-Castaño JD; Osman I; Fernandez F; Medina R; Vargas B; Japón-Rodríguez M; Sancho P; Perez-Valderrama B; Praena-Fernández JM; Duran I
Clin Transl Oncol; 2019 Jun; 21(6):796-804. PubMed ID: 30470992
[TBL] [Abstract][Full Text] [Related]
30. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
31. Results of a policy of surveillance in stage I testicular seminoma.
Warde PR; Gospodarowicz MK; Goodman PJ; Sturgeon JF; Jewett MA; Catton CN; Richmond H; Thomas GM; Duncan W; Munro AJ
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):11-5. PubMed ID: 8365931
[TBL] [Abstract][Full Text] [Related]
32. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
Fischer S; Tandstad T; Cohn-Cedermark G; Thibault C; Vincenzi B; Klingbiel D; Albany C; Necchi A; Terbuch A; Lorch A; Aparicio J; Heidenreich A; Hentrich M; Wheater M; Langberg CW; Ståhl O; Fankhauser CD; Hamid AA; Koutsoukos K; Shamash J; White J; Bokemeyer C; Beyer J; Gillessen S;
J Clin Oncol; 2020 Apr; 38(12):1322-1331. PubMed ID: 31877087
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma.
Choo R; Thomas G; Woo T; Lee D; Kong B; Iscoe N; Danjoux C; Klotz L; Morton G; Chander S
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):736-40. PubMed ID: 15708251
[TBL] [Abstract][Full Text] [Related]
34. Excellent survival in relapsed stage I testicular cancer.
Speicher P; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Beyer J; Akhoundova D
BMC Cancer; 2023 Sep; 23(1):870. PubMed ID: 37715132
[TBL] [Abstract][Full Text] [Related]
35. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience.
Akdag G; Alan O; Dogan A; Yuksel Z; Yildirim S; Kinikoglu O; Kudu E; Surmeli H; Odabas H; Yildirim ME; Turan N
World J Urol; 2023 Aug; 41(8):2201-2207. PubMed ID: 37351618
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience.
Chau C; Cathomas R; Wheater M; Klingbiel D; Fehr M; Bennett J; Markham H; Lee C; Crabb SJ; Geldart T
Ann Oncol; 2015 Sep; 26(9):1865-1870. PubMed ID: 26037797
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
39. Testicular seminoma: Are clinical features and treatment outcomes any different in India?
Anjanappa M; Kumar A; Mathews S; Joseph J; Jagathnathkrishna KM; James FV
Indian J Cancer; 2017; 54(1):385-387. PubMed ID: 29199728
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for loss to follow-up during active surveillance of patients with Stage I seminoma.
Endo T; Kawai K; Kamba T; Inai H; Uchida K; Miyazaki J; Kamoto T; Ogawa O; Nishiyama H
Jpn J Clin Oncol; 2014 Apr; 44(4):355-9. PubMed ID: 24558127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
